Status:
TERMINATED
Is Initial Response to Low Dose Risperidone Predictive for Outcome in Anxiety?
Lead Sponsor:
Marion Trousselard
Conditions:
Anxiety State
Eligibility:
All Genders
18-50 years
Phase:
PHASE3
Brief Summary
Risperidone at low dosage is often used as treatment of acute anxiety symptom. However, patients may be either responder or not. Here we hypothesized that the early response to a low dose of risperido...
Detailed Description
Risperidone at low dosage is often used as treatment of acute anxiety symptom. However, patients may be either responder or not. Here we hypothesized that the early response to a low dose of risperido...
Eligibility Criteria
Inclusion
- anxiety (score above 11 at anxiety scale of HADs)
- To have a prescription for 0.5 mg risperidone/day
- To give the consent
- To have a social protection
- To be adult (18-50 years)
Exclusion
- Psychiatric antecedents
- any treatment for mental disease (antidepressant, anxiolytics, etc.)
- Ongoing neurological pathologies
- Scheduled surgery
- addiction
- pregancy
- known intolerance to risperidone
- participation to another biomedical study
Key Trial Info
Start Date :
September 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2021
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT03227562
Start Date
September 1 2017
End Date
December 1 2021
Last Update
August 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Marion Trousselard
Brétigny-sur-Orge, Not in US/Canada, France, 91223